Form 4: DBV Technologies CEO Granted 964,000 Stock Options

DBV Technologies S.A. CEO Daniel Tasse was granted 964,000 employee stock options with an exercise price of $2.9, vesting over four years.

Summary

• Daniel Tasse, Chief Executive Officer and Director of DBV Technologies S.A. (DBVT), was granted 964,000 employee stock options.
• The transaction date for this grant was November 21, 2025.
• The exercise price for these options is $2.9 per share, which reflects a conversion from EURO at an exchange rate of $1.15154 to EURO 1.00 as of November 21, 2025.
• The options will vest in four equal annual installments, commencing on November 21, 2026.
• Vesting is contingent upon Daniel Tasse continuing to provide service to the company through each vesting date.
• The options have an expiration date of November 21, 2035.
• Following this transaction, Daniel Tasse beneficially owns 964,000 derivative securities (employee stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to the CEO is generally viewed as a positive for shareholder alignment and management retention, indicating confidence in the company's future. However, as a Form 4, it does not provide operational or financial performance data to significantly shift overall sentiment.

Positives

• The grant of a significant number of stock options to the CEO aligns management's long-term interests with those of shareholders, incentivizing performance and growth.
• The vesting schedule over four years demonstrates a commitment to long-term leadership and stability at the executive level.

Future Outlook

The options' vesting schedule, commencing in November 2026 and extending over four years, indicates a forward-looking incentive structure designed to retain the CEO and align his performance with the company's long-term strategic goals and shareholder value creation.

Industry Context

Executive stock option grants are a common form of compensation in the biotechnology and pharmaceutical industries, used to attract, retain, and motivate key leadership by linking their personal wealth to the company's stock performance. This grant to DBV Technologies' CEO is consistent with typical executive compensation practices aimed at fostering long-term commitment and shareholder alignment.

Comparison to Industry Standards

• The grant of stock options to a Chief Executive Officer is a standard practice in the biotech industry, similar to compensation structures seen at companies like Moderna or BioNTech, where executive incentives are often tied to long-term equity performance.
• A four-year vesting schedule is typical for executive equity awards, comparable to industry benchmarks designed to ensure sustained leadership and strategic execution over a multi-year horizon.

Corporate Governance

Related Party Transactions

• The grant of 964,000 employee stock options to Daniel Tasse, the Chief Executive Officer and a Director, constitutes a transaction between the company and a related party. This is a standard form of executive compensation.

Stakeholder Impact

• Shareholders: The option grant aligns the CEO's financial interests with shareholder value creation, potentially leading to more focused long-term strategic decisions. However, future exercise of options could lead to minor dilution.
• Employees: The compensation structure for the CEO may set a precedent or reflect the company's overall approach to executive incentives.
• Management: The options serve as a significant incentive for the CEO to remain with the company and drive its success over the next decade.

Next Steps

• The options will begin to vest in four equal annual installments starting November 21, 2026, subject to the CEO's continued service.

Key Dates

Keywords

DBV Technologies, DBVT, stock options, executive compensation, insider transaction, CEO, Daniel Tasse, equity grant, Form 4